SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests and that recently reported it had received a CE marking for its COVID-19 coronavirus assay, announced today that it has been requested to speak at the 27th Annual Molecular Medicine Tri-Conference, held March 1-4, 2020 in San Francisco, California.
The Molecular Med Tri-Con is presented by the Cambridge Healthtech Institute and regarded as the most comprehensive, industry-leading event covering precision medicine and diagnostics today. Following an introduction by Duncan MacCannell, CSO of the Office of Advanced Molecular Detection, Centers for Disease Control and Prevention, Company CEO Dwight Egan will deliver the presentation, titled “COVID-19 Coronavirus Emergency Response Test Development Utilizing Co-Diagnostics CoPrimer™ Technology,” on March 3 at 11:10 am. The presentation comes less than a week after cases of the novel coronavirus of unknown origin have been found in California.
Mr. Egan remarked, “Following the first reported COVID-19 deaths in the US and the Food and Drug Administration’s change in policy to expedite availability of tests, discussing Co-Diagnostics’ role in addressing the coronavirus epidemic with such a highly regarded audience couldn’t be more timely. In the space of about a month, our CoPrimer technology allowed us to design, develop, receive regulatory approval for, and begin marketing detection tools to aid in stemming the tide of this fast-spreading disease.
“We are honored to present our rapid response to this current outbreak to the attendees at Tri-Con. Co-Diagnostics also feels confident that this response is one that could be replicated whenever needed, as we pursue our mandate of making molecular diagnostic solutions accessible to all nations of the world, in addition to quickly providing updated versions of our COVID-19 test in the event of a mutation.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (viii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
